No Data
No Data
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58
Wells Fargo analyst Yanan Zhu maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating, and maintains the target price at $58.According to TipRanks data, the analyst has a success rate of 42.0% an
COVID-19 Vaccine Makers Rebound Amid Post-pandemic Prospects
Express News | Achilles Therapeutics Announces Research Collaboration With Arcturus Therapeutics to Explore Second-Generation Personalized Mrna Cancer Vaccines
CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogeni
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and